Intra-Cellular Therapies

Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company that is developing novel drugs for the treatment of diseases and disorders of the Central Nervous System (CNS). Building on the science generated from the Nobel Prize winning laboratory of Dr. Paul Greengard at The Rockefeller University, the Company develops compounds that have the potential to treat a wide range of diseases associated with the central nervous system. To aid in the development process, the Company incorporates its CNSProfile™, a state-of-the-art platform that allows ITI to choose compounds with the strongest potential to succeed in these difficult to treat diseases

New York, US
Size (employees)
41 (est)+11%
Intra-Cellular Therapies is headquartered in New York, US

Intra-Cellular Therapies Office Locations

Intra-Cellular Therapies has an office in New York
New York, US (HQ)
3960 Broadway

Intra-Cellular Therapies Metrics

Intra-Cellular Therapies Financial Metrics

Revenue (2016)

$330.7 k

Net income (2016)

($116.4 m)

Market capitalization (21-Mar-2017)

$641.4 m

Closing share price (21-Mar-2017)


Cash (31-Dec-2016)

$48.6 m
Intra-Cellular Therapies's current market capitalization is $641.4 m.
Intra-Cellular Therapies's revenue was reported to be $330.7 k in FY, 2016 which is a 262% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016


$2.7 m$577.3 k$91.4 k$330.7 k

Revenue growth, %


R&D expense

$21.2 m$87.7 m

General and administrative expense

$10.3 m$18.2 m

Operating expense total

$29 m$31.6 m$105.9 m$118.6 m


($26.3 m)($31 m)($105.8 m)($118.3 m)

EBIT margin, %


Interest expense

$613 k$7.1 k$36.8 k

Interest income

$29.6 k$303.9 k$1 m$2.9 m

Pre tax profit

($30.7 m)($104.8 m)($115.4 m)

Income tax expense

($18 k)$1.6 k$1.6 k$1.1 m

Net Income

($26.9 m)($30.7 m)($104.8 m)($116.4 m)
FY, 2013FY, 2014FY, 2015FY, 2016


$35.2 m$61.3 m$47.2 m$48.6 m

Accounts Receivable

$336.3 k$51.6 k$30.7 k$94.3 k


$762.2 k$1.3 m$8 m$4 m

Current Assets

$38.2 m$131 m$483.3 m$388.2 m


$68.3 k$54.6 k$775.5 k$627.6 k

Total Assets

$38.4 m$131.1 m$484.1 m$388.9 m

Accounts Payable

$3.4 m$2.1 m$1.6 m$3.8 m

Current Liabilities

$6.8 m$10.6 m$6.3 m$10.5 m

Additional Paid-in Capital

$89.2 m$208.9 m$669.9 m$685.3 m

Retained Earnings

($57.6 m)($88.3 m)($193 m)($309.5 m)

Total Equity

$31.6 m$120.6 m$476.2 m$375.5 m

Financial Leverage

1.2 x1.1 x1 x1 x
FY, 2014FY, 2015FY, 2016

Net Income

($30.7 m)($104.8 m)($116.4 m)

Depreciation and Amortization

$25.5 k$139.6 k$196.9 k

Accounts Receivable

$284.7 k$20.9 k($63.7 k)


Accounts Payable

($1.3 m)($419.9 k)$2.1 m

Cash From Operating Activities

($22.8 m)($102.3 m)($91.3 m)

Purchases of PP&E

($11.8 k)($860.6 k)($49 k)

Cash From Investing Activities

($66.7 m)($361.8 m)$92.3 m

Cash From Financing Activities

$115.7 m$449.9 m$477.7 k

Interest Paid

$7.1 k$7.1 k$36.8 k

Income Taxes Paid

$45 k$1 m

Intra-Cellular Therapies Operating Metrics

Intra-Cellular Therapies's Patent Families was reported to be 80 in FY, 2017
FY, 2017

Patent Families


Intra-Cellular Therapies Market Value History

Intra-Cellular Therapies Revenue Breakdown

Intra-Cellular Therapies News

Intra-Cellular Therapies Company Life

You may also be interested in